NDRC on future separate drug pricing: 15-30% markup possible, none for EDL, GBI

Release Date: 2009-09-14

The National Development and Reform Commission (NDRC) is drawing up the draft for the `Measures for the Administration of Drug Price', China Times reported September 11. According to the draft, drugs afforded separate pricing may enjoy a 30% markup over similar drugs with unified pricing.

Chemical drugs with innovative active pharmaceutical ingredients (API) will enjoy a 20% markup and those with innovative formulations will enjoy a 15% markup. Traditional Chinese medicines (TCM) with innovative APIs may have a 30% markup while those with innovative formulations will have a 25% markup.

An official from the NDRC said the draft still needs to be modified and some drugs may receive markups of over 30%. Additionally, the official confirmed the rumor that national essential drugs will not receive separate pricing; however, current separately- priced drugs that are included on the essential drug list will be allowed to keep their prices during the transition period before all essential drugs are set with unified pricing.
Type: NORMAL
Company: GBI
Country: China
Url: http://www.gbipharma.com/cpbheadline.asp?newsid=2010556
 
This website requires Flash Player 9 or later. If you can not view this site you probably need to update your system with this plug-in for your browser.